Search - tctmd.com

Displaying 61 - 80 of 83

Sort: Relevancy | Date

News Conference News EuroPCR 2019

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

Shelley Wood

May 23, 2019

News Industry News

Pi-Cardia Successfully Completes First-in-Human Studies with Novel Non-implant Based Treatment of Aortic Stenosis

May 07, 2019

News Conference News ACC 2019

TAVR in Bicuspid Aortic Stenosis Safe, Feasible in Selected Real-World Patients

Yael L. Maxwell

March 17, 2019

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Shelley Wood

March 11, 2019

News Industry News

Medtronic Announces Clinical Study of Transcatheter Aortic Valve Replacement in Aortic Stenosis Patients with Bicuspid Valves

September 18, 2018

News Daily News

TAVR Without Balloon Aortic Valvuloplasty: Increasingly Common, With Similar Outcomes

Yael L. Maxwell

September 17, 2018

News Conference News CRT 2018

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Michael O'Riordan

March 05, 2018

News Daily News

Surgical Aortic Valve Repair Effective, Durable in Experienced Hands

Caitlin E. Cox

December 21, 2017

News Conference News PCR London Valves 2017

CT Scans Before and After TAVR Show Tricuspid, Bicuspid Valves Are Reassuringly Similar

Shelley Wood

September 28, 2017

News Conference News PCR London Valves 2017

TAVR Takeover? Experts Debate Timing of Surgery’s Ousting in Aortic Stenosis

Shelley Wood

September 24, 2017

News Daily News

One in 10 TAVR Patients Treated Off-Label: TVT Registry

Michael O'Riordan

June 22, 2017

News Conference News EuroPCR 2017

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Michael O'Riordan

May 17, 2017

News Conference News ACC 2017

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

Shelley Wood

March 24, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News TCT 2016

Debate Over Low-Risk TAVR Hinges on Definition of Patient Population and Shared Decision-Making

Yael L. Maxwell

November 02, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

TAVR for Bicuspid Aortic Valve Stenosis Feasible, but Associated With Higher Rate of Permanent Pacemaker Implantation

Michael O'Riordan

July 05, 2016

News Daily News

Más de 1 de cada 10 Pacientes del Registro norteamericano TAVR Tratados Fuera de indicación

Shelley Wood

November 12, 2015

News Daily News

More Than 1 in 10 Patients in US TAVR Registry Treated Off-Label

Shelley Wood

November 11, 2015

News Industry News

Direct Flow Medical, Inc Announces FDA Approval to Broaden SALUS U.S. Pivotal Trial

April 09, 2015

Advertisement

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

Pi-Cardia Successfully Completes First-in-Human Studies with Novel Non-implant Based Treatment of Aortic Stenosis

TAVR in Bicuspid Aortic Stenosis Safe, Feasible in Selected Real-World Patients

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Medtronic Announces Clinical Study of Transcatheter Aortic Valve Replacement in Aortic Stenosis Patients with Bicuspid Valves

TAVR Without Balloon Aortic Valvuloplasty: Increasingly Common, With Similar Outcomes

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Surgical Aortic Valve Repair Effective, Durable in Experienced Hands

CT Scans Before and After TAVR Show Tricuspid, Bicuspid Valves Are Reassuringly Similar

TAVR Takeover? Experts Debate Timing of Surgery’s Ousting in Aortic Stenosis

One in 10 TAVR Patients Treated Off-Label: TVT Registry

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Debate Over Low-Risk TAVR Hinges on Definition of Patient Population and Shared Decision-Making

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

TAVR for Bicuspid Aortic Valve Stenosis Feasible, but Associated With Higher Rate of Permanent Pacemaker Implantation

Más de 1 de cada 10 Pacientes del Registro norteamericano TAVR Tratados Fuera de indicación

More Than 1 in 10 Patients in US TAVR Registry Treated Off-Label

Direct Flow Medical, Inc Announces FDA Approval to Broaden SALUS U.S. Pivotal Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content